

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Three polyoxygenated cyclohexenes from *Uvaria calamistrata*

Guang-Xiong Zhou^a; Yan-Jun Zhang^b; Ruo-Yun Chen^b; De-Quan Yu^b

^a Key Laboratory of Pharmacodynamic Constituents of TCM and New Drug Research, Institute of Traditional Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou, China

^b Institute of Materia Medica, Chinese Academy of Medical Science, Beijing, China

Online publication date: 11 August 2010

To cite this Article Zhou, Guang-Xiong , Zhang, Yan-Jun , Chen, Ruo-Yun and Yu, De-Quan(2010) 'Three polyoxygenated cyclohexenes from *Uvaria calamistrata*', Journal of Asian Natural Products Research, 12: 8, 696 – 701

To link to this Article: DOI: 10.1080/10286020.2010.482248

URL: <http://dx.doi.org/10.1080/10286020.2010.482248>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ORIGINAL ARTICLE

Three polyoxygenated cyclohexenes from *Uvaria calamistrata*

Guang-Xiong Zhou^{a*}, Yan-Jun Zhang^b, Ruo-Yun Chen^b and
De-Quan Yu^{b*}

^aKey Laboratory of Pharmacodynamic Constituents of TCM and New Drug Research, Institute of Traditional Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China; ^bInstitute of Materia Medica, Chinese Academy of Medical Science, Beijing 100050, China

(Received 4 December 2009; final version received 30 March 2010)

Three new polyoxygenated cyclohexenes, named uvacanols F, G, H (**1–3**), were isolated from the roots of *Uvaria calamistrata* (Annonaceae). Their structures were determined to be 2-acetoxy-5-chlorine-benzoyloxymethylcyclohex-1 (6)-ene-4-ol-3-benzoate (**1**), benzoyloxy-methylcyclohex-1 (6)-ene-2,3,4-triols-5-benzoate (**2**), 3-acetoxy-benzoyloxymethylcyclohex-1 (6)-ene-4,5-diols-2-benzoate (**3**) by spectroscopic methods and chemical derivatization.

Keywords: Annonaceae; *Uvaria calamistrata*; polyoxygenated cyclohexenes; uvacanols F, G, H

1. Introduction

Polyoxygenated cyclohexenes (PCs) are a type of constituent with the basic skeleton of hydroxymethyl-cyclohexene. These compounds usually have one double bond and four chiral carbons in the ring, and one oxygen-containing group attached at each stereocenter. Due to the variation of the location of the double bond and the number and position of the attached groups including ethoxyl, methoxyl, hydroxyl, acetoxy, and benzoate, PCs exhibited a variety of structures. A few of them exhibited *in vitro* antitumor activities [1] and others showed biological activities. The plants from the genus *Uvaria* were claimed to be the plentiful resource for PCs. So far, about 40 PC-type compounds were discovered in plants from the genus *Uvaria* [2–14]. A few PCs were also found in the plants of Piperaceae, Euphorbiaceae, and Zingiberaceae [15–18].

The annonaceous plant *Uvaria calamistrata* is distributed in the Hainan Island of China [19]. In our search for natural antitumor products from the plant in southern China, we found that the ethanolic extract of this plant exhibited significant inhibitory activity on some tumor cell lines. Our earlier papers had reported the isolation of a series of annonaceous acetogenins from the extract [20,21]. We also found that the ethanolic extract was rich in PCs. Several PCs were also isolated from this plant (Figure 1) [22]. This paper reports the results of our further investigation on PCs from this plant.

2. Results and discussion

Compound **1** was obtained as a colorless gum. The molecular formula of **1** was determined to be C₂₃H₂₁O₇Cl by HR-ESI-MS at *m/z* 445.1030. The presence of

*Corresponding authors. Email: dqquanyu@public.bta.net.cn; guangxzh@sina.com




Figure 1. Structures of compounds **1**–**3**.

chlorine was determined from the $[M + 2]^+$ isotopic peak at m/z 447 with about 1/3 relative abundance of M^+ . The fragment ions at m/z 105 and 77 in EI-MS and IR absorption bands at 1705 and 1272.9 cm^{-1} indicated the presence of a benzoate. Twelve aromatic carbon signals and two carboxyl signals at δ 164.4 and 164.2 in the ^{13}C NMR spectrum and 10 aromatic protons (in the ratio of 2:1:2 in three groups) between δ 8.06 and 7.24 in the ^1H NMR spectrum confirmed that **1** was a bis-benzoate. Carbons at δ 169.5 and 19.2 and protons at δ 2.06 suggested the presence of an acetoxy group. The proton signals of an olefinic methine, four oxygenated methines, and one methylene between δ 4.0 and 6.5 in the ^1H NMR spectrum and the corresponding carbons in the ^{13}C NMR spectrum suggested the basic skeleton of hydroxymethyl-cyclohexene-1 (6)-ene of **1**, similar to the PCs reported earlier. The relative configuration of the molecule was also identical to uvacanol A or conduritol A due to the similar J values from H-2 to H-6 [22]. The successive correlations of protons at δ 5.93, 5.60, 4.40, 4.67, and 6.17 in the ^1H – ^1H COSY spectrum and the J values between them confirmed the relative configuration. Two benzoates were located at C-3 and C-7 by the comparison of chemical shifts of the protons with those of uvacanol A [22]. The

acetoxy group was attached at C-2 due to the HMBC correlation between the proton at δ 5.93 and the carbon at δ 169.5. A chlorine atom was attached at C-5 due to the lack of esterification shift of H-5 and the obvious downfield shift of H-4 after the acetyl derivation of **1** with Ac_2O /pyridine. The C_1 – C_6 double bond of **1** was hydrogenated with hydrogen gas (H_2) and platinum–charcoal (Pt/C) in the pressured methanol solution to afford **1a**. The absolute stereochemistry of C-4 was elucidated to be *R* from the analysis of ^1H NMR spectra of 4*s*- and 4*r*- α -methoxy- α -(trifluoromethyl)phenylacetic acid (MTPA) ester derivatives. The positive $\Delta\delta$ (*s* – *r*) value for H-5 and H-6 and the negative $\Delta\delta$ (*s* – *r*) value for H-2 and H-3 determined the absolute configuration of C-4 to be *R*. So, C-2, C-3, and C-5 were elucidated as 2*R*, 3*S*, and 5*S* from its relative configuration, respectively, identical to those in uvacanol A. Thus, the structure of **1** was determined as 2*R*,3*S*,4*R*,5*S*-2-acetoxy-5-chlorine-benzoyloxymethylcyclohex-1 (6)-ene-4-ol-3-benzoate, named uvacanol F.

Compound **2** has the molecular formula $\text{C}_{21}\text{H}_{20}\text{O}_7$ due to the quasi-molecular ion at m/z 385.1270 in HR-ESI-MS. The IR, ^1H and ^{13}C NMR spectra of **2** were similar to those of **1**, except the absence of acetoxy group and the replacement of the Cl atom by the OH group. So, **2** was also a PC-type compound. The ^1H NMR spectrum of **2** revealed the presence of two benzoate groups. The successive correlations of protons at δ 4.52 (d, $J = 7.4$ Hz), 3.90 (d, $J = 7.4$ Hz), 4.51 (s), 5.76 (s), and 5.85 (s) and their J values of the acetylation derivative of **2** indicated that it had the same relative configuration as **1**. The two benzoate groups were elucidated to be at C-5 and C-7 on the basis of the chemical shift of H-5 (δ 5.76) and H-7. The ^{13}C NMR spectrum (see Table 2) of **2** further substantiated the structural elucidation. Based on the consideration of the same biogeneric route of **2** with **1**, compound **2**

was assumed to have the same absolute configurations at C-2, C-3, C-4, and C-5. The *cis*-diols at C-3 and C-4 in **2** were acetonated with 2,2-dimethoxyl propane to give ketal derivative **2a**, further confirming the relative configuration. Thus, the structure of compound **2** was confirmed as 2*R*,3*S*,4*R*,5*S*-benzoyloxymethylcyclohex-1 (6)-ene-2,3,4-triols-5-benzoate, named uvacanol G.

Compound **3** has the molecular formula C₂₃H₂₂O₈ due to the quasi-molecular ion at *m/z* 427.1365 in HR-ESI-MS. The IR, ¹H, and ¹³C NMR spectra of **3** were also similar to those of **1**. So, **3** also belonged to a PC-type compound. The ¹H NMR spectrum revealed that **3** contained two benzoxyl groups and one acetoxyl group. The successive correlations of protons at δ 5.70 (d, *J* = 4.2 Hz), 5.49 (dd, *J* = 4.2, 2.4 Hz), 4.13 (d, *J* = 7.2, 2.4 Hz), 4.46 (d, *J* = 7.2 Hz), and 6.15 (s) and their *J* values indicated the similar relative configuration of **3** to **1**. The two benzoxyl groups and one acetoxyl group were elucidated to be at C-2, C-7, and C-3, respectively, due to the HMBC correlation between the proton at δ 5.70 and the carbon at δ 169.9. Based on the consideration of the same biogeneric route as **1** and **2**, compound **3** was assumed to have the same absolute configurations at C-2, C-3, C-4, and C-5. Thus, the structure of **3** was elucidated as 2*R*,3*S*,4*R*,5*S*-3-acetoxyl-benzoyloxymethylcyclohex-1 (6)-ene-4,5-diols-2-benzoate, named uvacanol H.

The cytotoxic assay by the MTT method against four human cancer cell lines, human epidermoid cancer cells (KB), human ileocecal carcinoma cells (HCT-8), human epithelial tumor cells (A2780), and human mammary adenocarcinoma cells (MCF-7), was performed following the procedure in [2]. Although these new compounds were isolated from the ethanolic extract of the title plant with antitumor activity, the result revealed that all the compounds were inactive at the test concentration (100 μg/ml) for these cell lines.

3. Experimental

3.1 General experimental procedures

Melting points were measured on a micromelting point apparatus and are uncorrected. The optical rotations were measured on a Perkin-Elmer 241 polarimeter. IR spectra were recorded on a Perkin-Elmer 683 spectrometer. ¹H and ¹³C NMR spectra were measured on a Bruker AM-500 spectrometer at 500 and 125 MHz, respectively, in CDCl₃ with the residual solvent CHCl₃ as the internal standard. EI-MS were performed on a VGZAB-2F spectrometer. ESI-MS were performed on a Finnigan LCQ Advantage MAX spectrometer. HR-ESI-MS were recorded on a Micromass Q-TOF mass spectrometer.

3.2 Plant material

Plant material was collected from the Jian-Feng mount on the Hainan Island and authenticated as *U. calamistrata*. A voucher specimen has been deposited at the Department of Botany, Institute of Materia Medica.

3.3 Extraction and isolation

The dried and pulverized roots (10 kg) of *U. calamistrata* were exhaustively extracted with 30 liters (× 3) of methanol under reflux. The extract solution was concentrated *in vacuo* to yield a 1980 g residue (F001), which was partitioned between H₂O and CHCl₃ (1:1), giving the CHCl₃-soluble extract (575 g) (F002), and the insoluble fraction (120 g) and water-soluble fraction (1100 g). The CHCl₃ extract was partitioned between 90% aqueous methanol and petroleum ether (1:1). The methanol layer yielded a 350 g residue, which was chromatographed on a silica gel (16–200 mesh, 3.5 kg) column eluting with the gradient petroleum ether–acetone solvent system. The eluted fractions with dark spots on a GF₂₅₄ Si thin layer plate under UV light

Table 1. ^1H NMR spectral data of compounds **1**–**3** (500 MHz, CDCl_3 , J in Hz).

No.	1	2	3
2	5.93 (d, $J = 5.6$)	4.52 (d, $J = 7.4$)	5.70 (d, $J = 4.2$)
3	5.60 (d, $J = 5.6, 2.2$)	3.90 (d, $J = 7.4$)	5.49 (dd, $J = 4.2, 2.4$)
4	4.40 (dd, $J = 5.9, 2.2$)	4.51 (s)	4.13 (dd, $J = 7.2, 2.4$)
5	4.67 (dd, $J = 5.9, 3.1$)	5.76 (s)	4.46 (d, $J = 7.2$)
6	6.17 (d, $J = 3.1$)	5.85 (s)	6.15 (s)
7	4.87 (s)	5.25 (d, $J = 13.0$), 4.79 (d, $J = 13.0$)	4.81 (s)
Ar	8.10–7.40 (m)	8.07–7.45 (m)	8.10–7.30 (m)
Ac	2.06 (s)		2.03 (s)

after development were repeatedly chromatographed to afford compounds **1** (200 mg), **2** (50 mg), and **3** (35 mg).

3.3.1 Uvacanol F (**1**)

Colorless gum, mp 57–58°C; $[\alpha]_{\text{D}}^{25} + 9.8$ ($c = 0.40$, MeOH); IR ν_{max} (KBr) cm^{-1} : 3452, 2925, 1721, 1697, 1603, 1315, 1273, 1070, 712; ^1H and ^{13}C NMR spectral data, see Tables 1 and 2; ESI-MS (positive) m/z : 467 $[\text{M} + \text{Na}]^+$; HR-ESI-MS (positive) m/z : 445.1030 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{23}\text{H}_{22}\text{O}_7\text{Cl}$, 445.1055).

3.3.1.1 (R)- and (S)-MTPA derivatives (1r and 1s). (R)- or (S)-MTPA, *N,N*-dicyclohexylcarbodiimide, and **1** in the molar ratio of 5:7:1 were added into 2 ml of anhydrous CH_2Cl_2 with a few crystals of 4-(dimethylamino)-pyridine. The mixture

was stirred at room temperature for 10 h. Comparative TLC with **1** was used to check the end of the reaction. The reacted solution was used for the purification of MTPA esters. The purified (R)- and (S)-MTPA derivative esters (**1r** and **1s**) of **1** were obtained by preparative TLC.

3.3.1.2 1s. ^1H NMR (CDCl_3 , 300 MHz) δ : 7.9 (2H, dd, $J = 8.1, 2.5$ Hz, Ar-H-2',6'), 7.82 (2H, dd, $J = 8.1, 2.5$ Hz, Ar-H-2'',6''), 7.57 (2H, dt, $J = 8.1, 2.4$ Hz, Ar-H-4',4''), 7.43 (5H, m, H-3',3'',5',5'', mtpa-H-4'''), 7.29 (4H, m, mtpa-H), 6.19 (1H, d, $J = 3.3$ Hz, H-6), 5.88 (1H, d, $J = 4.2$ Hz, H-2), 5.74 (1H, dd, $J = 4.2, 2.4$ Hz, H-3), 5.72 (1H, dd, $J = 5.7, 2.4$ Hz, H-4), 4.89 (1H, s, H-7), 4.83 (1H, d, $J = 5.7, 3.3$ Hz, H-5), 3.52 (3H, s, mtpa-OMe), 2.09 (3H, s, OAc).

Table 2. ^{13}C NMR spectral data of compounds **1**–**3** (125 MHz, CDCl_3).

No.	1	2	3
1	133.0	137.5	131.0
2	67.5	68.7	68.2
3	72.5	73.8	73.2
4	56.7	70.1	71.7
5	72.1	71.7	69.1
6	129.8	121.5	131.7
7	64.4	64.0	64.4
1'	129.5, 129.4	129.8, 129.7	131.7
2', 6'	129.2, 129.0	129.3, 129.0	129.6, 129.8
3', 5'	128.6, 128.3	128.4, 128.2	128.4, 128.5
4'	132.2	132.9	133.2, 133.5
7'	164.2, 164.4	165.2	166.0, 166.3
Ac	169.5, 19.2		169.9, 20.7

3.3.1.3 **Ir.** ^1H NMR (CDCl_3 , 300 MHz) δ : 7.97 (2H, dd, $J = 8.1$, 2.4 Hz, Ar-H-2',6'), 7.93 (2H, dd, $J = 8.1$, 2.5 Hz, Ar-H-2'',6''), 7.61 (2H, dt, $J = 8.1$, 2.4 Hz, Ar-H-4'), 7.58 (1H, dt, $J = 8.1$, 2.4 Hz, H-4''), 7.53 (1H, t, $J = 8.1$ Hz, mtpa-Ar-H4), 7.40 (4H, m, H-3',3'',5',5''), 7.28 (4H, m, mtpa-Ar-H), 6.13 (1H, d, $J = 3.0$ Hz, H-6), 6.02 (1H, d, $J = 6.6$ Hz, H-2), 5.84 (1H, dd, $J = 6.6$, 2.4 Hz, H-3), 5.80 (1H, dd, $J = 5.4$, 2.4 Hz, H-4), 4.83 (2H, d, $J = 13.4$ Hz, H-7), 4.70 (1H, d, $J = 5.4$, 3.0 Hz, H-5), 3.49 (3H, s, mtpa-OMe), 2.07 (3H, s, OAc).

3.3.1.4 Hydrogenated derivative (**1h**).

An excess of activated Pt/C was added to a solution of **1** in EtOH (10 ml). The reaction mixture was filled with hydrogen gas under 5 air pressures at room temperature in a hydrogenation reactor and shaken for 24 h. The solvent was filtered, and the reacted product (**1h**) in the solution was purified by flash column chromatography with the petroleum ether–acetone eluant system. ^1H NMR (CDCl_3 , 300 MHz) δ : 8.03 (4H, m, H-2',2'',6',6''), 7.57 (2H, m, Ar-H-4',4''), 7.52 (4H, m, Ar-H-3',3'',5',5''), 6.09 (1H, m, H-3), 6.00 (1H, d, $J = 5.7$ Hz, H-2), 5.36 (1H, dd, $J = 6.0$, 2.4 Hz, H-4), 4.77 (2H, s, H-7), 4.38 (1H, dt, $J = 6.0$, 3.3 Hz, H-5), 2.64 (1H, d, $J = 18.3$ Hz, H-6a), 2.45 (1H, dd, $J = 18.3$, 3.3 Hz, H-6b), 2.16 (1H, br s, H-1).

3.3.1.5 Acetyl derivative (**1a**).

A small amount (10 mg) of **1** was treated with Ac_2O /pyridine at room temperature for 12 h. Preparative TLC of the reacted solution yielded the purified mono acetyl derivative **1a** (gum, 8 mg): colorless crystal, mp 75–76°C; $[\alpha]_{\text{D}}^{22} + 21.4$ ($c = 0.11$, MeOH); IR ν_{max} (film) cm^{-1} : 3063, 2953, 1724, 1601, 1450, 1271, 1113, 1026, 712; ^1H NMR (CDCl_3 , 300 MHz) δ : 7.99 (4H, t, $J = 8.1$ Hz, Ar-H-2',6',2'',6''), 7.57 (2H, m, Ar-H-4',4''), 7.39 (4H, t, $J = 8.1$ Hz, Ar-H-3',5',3'',5''), 6.17 (1H, d, $J = 2.7$ Hz, H-6),

5.93 (1H, d, $J = 5.7$ Hz, H-2), 5.70 (1H, dd, $J = 5.7$, 2.4 Hz, H-3), 5.53 (1H, dd, $J = 5.7$, 2.4 Hz, H-4), 4.88 (2H, s, H-7), 4.72 (1H, dd, $J = 5.7$, 2.7 Hz, H-5), 2.11 (3H, s, Ac), 2.09 (3H, s, Ac); ^1H NMR ($\text{DMSO}-d_6$, 300 MHz) δ : 8.03 (2H, d, $J = 8.1$ Hz, Ar-H), 7.98 (2H, d, $J = 8.1$ Hz, Ar-H), 7.65 (2H, dq, $J = 8.1$ Hz, Ar-H), 7.51 (4H, q, $J = 8.1$ Hz, Ar-H), 5.63 (1H, s, H-6), 5.50 (1H, s, H-5), 4.93 (1H, d, $J = 13.3$ Hz, H-7a), 4.82 (1H, d, $J = 13.3$ Hz, H-7b), 4.24 (1H, d, $J = 7.4$ Hz, H-2), 4.14 (1H, d, $J = 1.7$ Hz, H-4), 3.57 (1H, dd, $J = 7.4$, 1.7 Hz, H-3); CI-MS m/z : 469 (0.5), 467 (1), 451 (20), 427 (35), 393 (3), 365 (4), 331 (2), 305 (1), 271 (2), 262 (1), 245 (4), 227 (5), 211 (5), 207 (1), 183 (1), 165 (3), 149 (4), 123 (25), 105 (100), 91 (12), 77 (8), 69 (4); EI-MS m/z (rel. int.): 451 (30) ($[\text{M} + \text{H} - \text{H}_2\text{O}]^+$), 427 ($[\text{M} + \text{H} - \text{Ac}]^+$), 365 (1), 331 (1), 269 (4), 262 (2), 244 (1), 227 (7), 207 (2), 165 (3), 123 (3), 105 (100), 94 (1), 77 (22), 51 (12), 43 (15).

3.3.2 Uvacanol G (**2**)

Colorless crystal, mp 156–157°C; $[\alpha]_{\text{D}}^{22} - 104.2$ ($c = 0.6$, MeOH); ^1H and ^{13}C NMR spectral data, see Tables 1 and 2; IR ν_{max} (KBr) cm^{-1} : 3450, 2922, 1720, 1699, 1601, 1315, 1273, 1069, 710; ESI-MS (positive) m/z : 407.6 ($[\text{M} + \text{Na}]^+$); CI-MS m/z (rel. int.): 385 (0.5) ($[\text{M} + \text{H}]^+$), 384 (1), 367 (30), 351 (1), 263 (30), 245 (5), 247 (3), 229 (4), 227 (3), 163 (2), 141 (12), 123 (100), 105 (82), 95 (13), 91 (4), 79 (11), 71 (7); HR-ESI-MS (positive) m/z : 385.1270 ($[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{21}\text{H}_{21}\text{O}_7$), 385.1287).

3.3.2.1 Acetonide derivative (**2a**).

A 10.0 mg amount of **2**, 0.1 ml of 2,2-dimethoxyl propane, and 1 ml of CH_2Cl_2 were mixed. The mixture was stirred with a magnetic stirrer at room temperature for 8 h, and then subjected to preparative TLC on a silica gel GF₂₅₄ plate to obtain **2a**: ^1H NMR (CDCl_3 , 400 MHz) δ : 8.11 (2H, d,

$J = 8.1$ Hz, Ar-H), 8.04 (2H, d, $J = 8.1$ Hz, Ar-H), 7.59 (2H, t, $J = 8.1$ Hz, Ar-H), 7.42 (4H, t, $J = 8.1$ Hz, Ar-H), 6.17 (1H, d, $J = 3.6$ Hz, H-6), 5.88 (1H, dd, $J = 3.0$, 3.6 Hz, H-5), 4.96 (2H, s, H-7), 4.76 (1H, dd, $J = 7.2$, 3.0 Hz, H-4), 4.57 (1H, d, $J = 3.0$ Hz, H-2), 4.53 (1H, dd, $J = 7.2$, 3.0 Hz, H-3), 1.36 (1H, s, Me), 1.35 (3H, s, Me).

3.3.3 Uvacanol H (3)

Mp 43–45°C; $[\alpha]_D^{22} - 24.9$ ($c = 0.3$, MeOH); IR ν_{\max} (KBr) cm^{-1} : 3452, 2924, 1722, 1601, 1452, 1330, 1273, 1223, 1175, 1113, 1075, 1026, 712; ^1H and ^{13}C NMR spectral data, see Tables 1 and 2; CI-MS m/z (rel. int.): 409 ($[\text{M} + \text{H}]^+ - \text{H}_2\text{O}$) (5), 367 ($[\text{MH}]^+ - \text{HOAc}$) (13), 351, 305 ($[\text{M} + \text{H}]^+ - \text{HOBz}$) (8), 287 ($[\text{M} + \text{H}]^+ - \text{H}_2\text{O} - \text{HOBz}$) (3), 262 ($[\text{M} + \text{H}]^+ - \text{HOBz} - \text{Bz}$) (2), 244 (12), 233 (3), 227 (4), 215 (3), 211 (15), 182 (3), 165 (3), 153 (4), 123 (5), 105 (100), 94 (10), 77 (15), 69 (8); ESI-MS (positive) m/z : 427 $[\text{M} + \text{Na}]^+$; HR-ESI-MS (positive) m/z : 427.1365 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{23}\text{H}_{23}\text{O}_8$, 427.1393).

Acknowledgements

We would like to thank Mr Si-Man Huang at the Center of Life Science, Hainan University for the collection of the plant material. HR-ESI-MS were measured at the Institute of Traditional Medicine and Natural Products, College of Pharmacy, Jinan University.

References

- [1] Y.H. Liao, L.Z. Xu, S.L. Yang, J. Dai, Y.S. Zhen, M. Zhu, and N.J. Sun, *Phytochemistry* **45**, 729 (1997).
- [2] Q.M. Xu, Z.M. Zou, L.Z. Xu, and S.L. Yang, *Chin. Chem. Lett.* **16**, 1343 (2005).
- [3] Q.M. Xu, Z.M. Zou, L.Z. Xu, and S.L. Yang, *Chem. Pharm. Bull.* **53**, 826 (2005).
- [4] S. Wang, R.Y. Chen, S.S. Yu, and D.Q. Yu, *J. Asian Nat. Prod. Res.* **5**, 17 (2003).
- [5] B. Akendengue, F. Roblot, P.M. Loiseau, C. Bories, E. Ngou-Milama, A. Laurens, and R. Hocquemiller, *Phytochemistry* **59**, 885 (2002).
- [6] Y. Takeuchi, Q. Cheng, Q.W. Shi, T. Sugiyama, and T. Oritani, *Biosci. Biotech. Biochem.* **65**, 1395 (2001).
- [7] Y.H. Liao, Z.M. Zou, J. Guo, L.Z. Xu, M. Zhu, and S.L. Yang, *J. Chin. Pharm. Sci.* **9**, 170 (2000).
- [8] G.X. Zhou, R.Y. Chen, and D.Q. Yu, *Chin. Chem. Lett.* **9**, 935 (1998).
- [9] X.P. Pan, R.Y. Chen, and D.Q. Yu, *Phytochemistry* **47**, 1063 (1998).
- [10] X.P. Pan, D.Q. Yu, C.H. He, and J.J. Chai, *Acta Pharm. Sin.* **32**, 530 (1997).
- [11] Y.H. Liao, L.Z. Xu, S.L. Yang, J. Dai, Y.S. Zhen, M. Zhu, and N.J. Sun, *Phytochemistry* **45**, 729 (1997).
- [12] W.M. Zhao, G.W. Qin, R.Z. Yang, T.Y. Jiang, W.X. Li, L. Scott, J.K. Snyder, and A. Tonkinenin, *Tetrahedron* **52**, 12373 (1996).
- [13] X.P. Pan and D.Q. Yu, *Phytochemistry* **40**, 1709 (1995).
- [14] X.P. Pan and D.Q. Yu, *Chin. Chem. Lett.* **6**, 305 (1995).
- [15] S.C. Taneja, S.K. Koul, P. Pushpangadan, K.L. Dhar, W.M. Daniewski, and W. Schilf, *Phytochemistry* **30**, 871 (1991).
- [16] S.M. Kupchan, R.J. Hemingway, and R.M. Smith, *J. Org. Chem.* **34**, 3898 (1969).
- [17] O. Pancharoen, P. Tuntiwachwuttikul, and W.C. Taylor, *Phytochemistry* **28**, 1143 (1989).
- [18] P. Tuntiwachwuttikul, O. Pancharoen, W.A. Bubb, T.W. Hambley, W.C. Taylor, and V. Reutrakul, *Aust. J. Chem.* **40**, 2049 (1987).
- [19] W.Y. Chun, H.C. Chang, and F.H. Chen, *Flora Hainanica* (Sciences Press, Beijing, 1964), Vol. 1, p. 235.
- [20] G.X. Zhou, L.E. Zhou, R.Y. Chen, and D.Q. Yu, *J. Nat. Prod.* **62**, 261 (1999).
- [21] G.X. Zhou, R.Y. Chen, Y.J. Zhang, and D.Q. Yu, *J. Nat. Prod.* **63**, 1201 (2000).
- [22] G.X. Zhou, Y.J. Zhang, R.Y. Chen, and D.Q. Yu, *J. Asian Nat. Prod. Res.* **2**, 227 (1999).